glp 1 gip vs tirzepatide Main physiological actions of the dual and GLP-1 agonist Tirzepatide, a dual GIP/GLP-1 receptor

Meanwhile, patients are looking for solutions to any number of conditions with the hope that new treatments can provide more options or, perhaps, better outcomes

Understanding your genetic predispositions and biomarker profile may help inform personalized treatment decisions with your provider

Yuma T, Tokuda M, Nishimoto N, Yokoi H, Izumori K

The global obesity crisis has sparked a multibillion-dollar showdown, with Novo and Eli Lilly locked in an intense battle for supremacy.

Investments are significant in the region, driving rapid product launches, clinical trials for new indications, and early adoption of innovative GLP-1 formulations, including oral and long-acting injectables